Pepto-Bismal efficacy studies for diarrhea. indication submitted to FDA.
D001729:Bismuth / Q000627:therapeutic use*; D003967:Diarrhea / Q000188:drug therapy*; D006801:Humans; D009942:Organometallic Compounds; D012459:Salicylates / Q000627:therapeutic use*
D009942:Organometallic Compounds; D012459:Salicylates; C015715:bismuth subsalicylate; D001729:Bismuth